Skip to main content

Currently Skimming:

2 The Biology of Ovarian Cancers
Pages 57-96

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 57...
... Ovarian cancer can arise from any of these cell types, but ovarian carcinomas (cancers with epithelial differentiation) make up the majority of ovarian cancers and are responsible for most ovarian cancer–related deaths (Kurman, 2013)
From page 58...
... , EC is one of the two major types of ovarian carcinoma with a well-defined association with endometriosis (ectopic endometrial tissue) (DePriest et al., 1992; Erzen et al., 2001; Yoshikawa et al., 2000)
From page 59...
... Metastases from LGSCs often manifest as small solid nests of tumor cells or as micropapillae surrounded by clear spaces or clefts that invade haphazardly into involved tissue. Despite the similarity in names, LGSCs infrequently progress to HGSCs, and, for the most part, the two types of ovarian carcinomas have non-overlapping mutational patterns (Vang et al., 2009)
From page 60...
... Ovarian Carcinoma Classification and Nomenclature The classification and nomenclature of ovarian carcinomas has evolved over many decades and may continue to evolve as the understanding of the carcinomas' origin and molecular features becomes more refined. Historically, more than one term has been used for some ovarian carcinoma types, which may have hindered progress in understanding their biology and clini
From page 61...
... In fact, detecting ovarian cancers early may require looking in locations other than the ovaries themselves, because a growing evidence base suggests that many ovarian carcinomas arise from sites outside the ovaries and spread to the ovaries secondarily. The Origins of HGSCs Historically, researchers and clinicians assumed that ovarian carcinomas develop from the ovarian surface epithelium (OSE)
From page 62...
... 62 FIGURE 2-1  Potential cellular origins of ovarian carcinomas. NOTES: Data suggest that many ovarian carcinomas may originate from outside the ovaries.
From page 63...
... . Recent work done in a mouse model suggests that ovarian carcinomas may arise from a susceptible population of cells with stem cell–like properties that are present where the OSE, FTE, and peritoneal mesothelium converge (Flesken-Nikitin et al., 2013; Ng and Barker, 2015)
From page 64...
... . The shared mutational spectrum of endometriosis-associated ovarian cancers and uterine ECs suggests a common origin, likely attributable to endometriosis.
From page 65...
... . Implications In summary, only a small fraction of ovarian carcinomas may actually originate in the ovaries, and in response to that understanding, a paradigm shift is occurring that is moving the focus away from seeing the ovaries as the source of most ovarian carcinomas (Kuhn et al., 2012)
From page 66...
... or promote (oncogenes) the growth of ovarian carcinomas.
From page 67...
... This gene growth, and migration is often mutated in cancer • PPP2R1A: regulates signaling pathways that inhibit cell growth and division CCC • KRAS • ARID1A • PIK3CA • PTEN • PPP2R1A • TP53 NOTE: The descriptions describe the functions of the proteins encoded by the genes listed above. SOURCES: Anglesio et al., 2013a; Belanger et al., 2015; Cancer Genome Atlas Research Network, 2011; Della Pepa et al., 2015; Garrett et al., 2001; Gemignani et al., 2003; Jones et al., 2010; McConechy et al., 2011, 2014; Merritt and Cramer, 2010; Ryland et al., 2015; I
From page 68...
... . Some of the previous genetic studies of serous carcinoma have been confounded by the inclusion of other, non-serous subtypes of ovarian carcinoma.
From page 69...
... , long noncoding RNA, and small RNA transcripts from DNA -- in a cell or tissue. Historically, the study of tumor-specific alterations to DNA represented the major focus in cancer research.
From page 70...
... TUMOR HETEROGENEITY Ovarian cancers are heterogeneous tumors that can change in various ways as the disease progresses. Only a few small studies have investigated these variations in a comprehensive manner.
From page 71...
... However, most cancers other than ovarian cancer have a variety of treatment options available to overcome resistance when a specific therapeutic is no longer effective. Ovarian cancer is hindered by the lack of additional therapeutic options, and therefore an improved understanding of the molecular mechanisms underlying drug resistance in ovarian carcinomas could be useful for devising new targeted therapeutic approaches to overcome or bypass resistance.
From page 72...
... The use of different drugs with non-overlapping mechanisms of action may also be an important approach to overcoming platinum and other types of drug resistance. TUMOR MICROENVIRONMENT Cancers form because of a series of mutations in oncogenes or tumor ­ suppressor genes, but the specific tumor microenvironment can shape the transcriptional and functional diversity of the resulting cancer cells (­ belson et al., 2013; Cancer Genome Atlas Research Network, 2011; A Hanahan and Weinberg, 2011; Myers et al., 2006; Schwarz et al., 2015; Tlsty and Coussens, 2006; Touboul et al., 2014)
From page 73...
... The Role of the Immune System in Ovarian Cancers Cancer cells evade immunological elimination by inducing the expression of T cell inhibitory receptors on tumor cells and immune cells and by recruiting immunosuppressive cells such as regulatory T cells and tumor
From page 74...
... . For example, metastatic ovarian carcinomas typically seed into the adipose tissue of the peritoneum, which results in the reprogramming of adipocytes to generate free fatty acids that are then used by the cancer cells to generate ATP.
From page 75...
... These cells may mediate tumor metastasis and, by virtue of their relative resistance to chemotherapy and radiotherapy, may contribute to the treatment resistance commonly seen in ovarian cancers (Zhang et al., 2008)
From page 76...
... Cell Culture Models Cancer cell lines are the most commonly used models in cancer research, and their use has advanced the understanding of cancer biology. However, because of the heterogeneity and the distinct molecular features of different ovarian carcinomas, not all ovarian cancer cell lines are representative of all ovarian cancers (see Table 2-2)
From page 77...
... tion, drug response, phenotypic heterogeneity, and changes in gene expression and cell behavior. A human fallopian tube co-culture system of both secretory and ciliated cells was developed from primary human surgical specimens (Fotheringham et al., 2011; Levanon et al., 2010)
From page 78...
... A number of GEMMs developed over the past several years are outlined in Table 2-3; no GEMM of mucinous ovarian carcinoma has yet been reported. Developing an ovarian cancer GEMM requires being able to modify the genes of interest in the cells of interest.
From page 79...
... • More research is needed to determine the sites of origin and the pathogenesis of each subtype because current evidence suggests that only a fraction of ovarian carcinomas originate in the ovaries. • More research is needed to better understand the multitude of ge netic alterations that characterize ovarian cancers in order to help
From page 80...
... Pten; Dicer ± MISIIR(Amhr2) -Cre FTE and Tumors with Pten and Dicer inactivation initiate in fallopian tube Kim et al., 2012, Trp53 OSE stroma.
From page 81...
... -Cre OSE Fan et al., 2009 Pten; KrasG12D MISIIR(Amhr2) -Cre OSE Mullany et al., 2011 ENDOMETRIOID CARCINOMA MODELS Pten; Arid1a AdCre into bursa OSE Endometrioid and/or undifferentiated carcinomas arise in Guan et al., 2014 ~60 percent of mice within 6 months and in ~80 percent of mice within 8–9 months Pten; Apc ± AdCre into bursa OSE Tumor phenotype is more aggressive with mutant Pik3ca or Trp53 Wu et al., 2013 Pik3caE545K or Trp53 Pten; Apc ± AdCre into bursa OSE Tumor phenotype is less aggressive and tumors display more Zhai et al., 2015 Arid1a epithelial differentiation with Arid1a loss Pten; MISIIR(Amhr2)
From page 82...
... 2013. Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis?
From page 83...
... 2013. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial muta tional profiling.
From page 84...
... 2010. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
From page 85...
... : An entity distinct from other ovarian carcinomas as sug gested by a nested case-control study. Gynecologic Oncology 83(1)
From page 86...
... 2006. Ovarian cancer cells polarize macrophages toward a tumor associated phenotype.
From page 87...
... 2012. High grade serous ovarian cancer arises from fallopian tube in a mouse model.
From page 88...
... 2007. Tumor irradiation increases the recruit ment of circulating mesenchymal stem cells into the tumor microenvironment.
From page 89...
... 2011. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
From page 90...
... 2014. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.
From page 91...
... 2003. BRCA1/2-related ovarian cancers are of tubal origin: A hypothesis.
From page 92...
... 2014. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
From page 93...
... Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells and Development 21(14)
From page 94...
... 2014. Reversing platinum resistance in high grade serous ovarian carcinoma: Targeting BRCA and the homologous recombination system.
From page 95...
... 2001. Simul taneously detected endometrial and ovarian carcinomas -- A prospective clinicopatho logic study of 74 cases: A Gynecologic Oncology Group Study.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.